

What is claimed is

A method of treating sexual dysfunction in a mammal comprising administering to a mammal in need of such treatment a therapeutically effective amount of a dopamine D<sub>4</sub> receptor agonist or a pharmaceutically acceptable salt thereof with the proviso that said dopamine D<sub>4</sub> receptor agonist is not 5,6,6a,7-tetrahydro-6-methyl-4H-dibenzo[de,g]quinoline-10,11-diol.

2. A method of treating male sexual dysfunction in a mammal comprising administering to a mammal in need of such treatment a therapeutically effective amount of a dopamine D<sub>4</sub> receptor agonist or a pharmaceutically acceptable salt thereof with the proviso that said dopamine D<sub>4</sub> receptor agonist is not 5,6,6a,7-tetrahydro-6-methyl-4H-dibenzo[de,g]quinoline-10,11-diol.

3. A method of treating female sexual dysfunction in a mammal comprising administering to a mammal in need of such treatment a therapeutically effective amount of a dopamine D<sub>4</sub> receptor agonist or a pharmaceutically acceptable salt thereof with the proviso that said dopamine D<sub>4</sub> receptor agonist is not 5,6,6a,7-tetrahydro-6-methyl-4H-dibenzo[de,g]quinoline-10,11-diol.

4. A method of treating male erectile dysfunction in a mammal comprising administering to a mammal in need of such treatment a therapeutically effective amount of a dopamine D<sub>4</sub> receptor agonist or a pharmaceutically acceptable salt thereof with the proviso that said dopamine D<sub>4</sub> receptor agonist is not 5,6,6a,7-tetrahydro-6-methyl-4H-dibenzo[de,g]quinoline-10,11-diol.

5. A method of treating sexual dysfunction in a mammal comprising administering to a mammal in need of such treatment a therapeutically effective amount of a selective dopamine D<sub>4</sub> receptor agonist or a pharmaceutically acceptable salt thereof.

6. A method of treating male sexual dysfunction in a mammal comprising administering to a mammal in need of such treatment a therapeutically effective amount of a selective dopamine D<sub>4</sub> receptor agonist or a pharmaceutically acceptable salt thereof.

5 7. A method of treating female sexual dysfunction in a mammal comprising administering to a mammal in need of such treatment a therapeutically effective amount of a selective dopamine D<sub>4</sub> receptor agonist or a pharmaceutically acceptable salt thereof.

8. A method of treating male erectile dysfunction in a mammal comprising  
10 administering to a mammal in need of such treatment a therapeutically effective amount of a selective dopamine D<sub>4</sub> receptor agonist or a pharmaceutically acceptable salt thereof.

9. The method of claim 6 wherein said selective dopamine D<sub>4</sub> receptor agonist is N-{[4-(2-cyanophenyl)-1-piperazinyl]methyl}-3-methylbenzamide or a pharmaceutically acceptable  
15 salt thereof.

10. The method of claim 7 wherein said selective dopamine D<sub>4</sub> receptor agonist is N-{[4-(2-cyanophenyl)-1-piperazinyl]methyl}-3-methylbenzamide or a pharmaceutically acceptable  
20 salt thereof.

11. The method of claim 8 wherein said selective dopamine D<sub>4</sub> receptor agonist is N-{[4-(2-cyanophenyl)-1-piperazinyl]methyl}-3-methylbenzamide or a pharmaceutically acceptable  
salt thereof.

12. The method of claim 6 wherein said selective dopamine D<sub>4</sub> receptor agonist is 5-fluoro-2-{[4-(2-pyridinyl)-1-piperazinyl]methyl}-1H-indole or a pharmaceutically acceptable  
25 salt thereof.

13. The method of claim 7 wherein said selective dopamine D<sub>4</sub> receptor agonist is 5-fluoro-2-{[4-(2-pyridinyl)-1-piperazinyl]methyl}-1H-indole or a pharmaceutically acceptable  
30 salt thereof.

14. The method of claim 8 wherein said selective dopamine D<sub>4</sub> receptor agonist is 5-fluoro-2-{{4-(2-pyridinyl)-1-piperazinyl}methyl}-1H-indole or a pharmaceutically acceptable salt thereof.

5 15. A method of claim 5 wherein said selective dopamine D<sub>4</sub> receptor agonist is 3 fold more selective for the D<sub>4</sub> receptor than for the D<sub>2</sub> receptor.

16. A method of claim 5 wherein said selective dopamine D<sub>4</sub> receptor agonist is 25 fold more selective for the D<sub>4</sub> receptor than for the D<sub>2</sub> receptor.

10

17. A method of claim 5 wherein said selective dopamine D<sub>4</sub> receptor agonist is 50 fold more selective for the D<sub>4</sub> receptor than for the D<sub>2</sub> receptor.

15

18. A method of claim 5 wherein said selective dopamine D<sub>4</sub> receptor agonist is 100 fold more selective for the D<sub>4</sub> receptor than for the D<sub>2</sub> receptor.

19. A method of claim 5 wherein said selective dopamine D<sub>4</sub> receptor agonist is 200 fold more selective for the D<sub>4</sub> receptor than for the D<sub>2</sub> receptor.

20

20. A method of claim 5 wherein said selective dopamine D<sub>4</sub> receptor agonist is 300 fold more selective for the D<sub>4</sub> receptor than for the D<sub>2</sub> receptor.

21. A method of claim 5 wherein said selective dopamine D<sub>4</sub> receptor agonist is 500 fold more selective for the D<sub>4</sub> receptor than for the D<sub>2</sub> receptor.

25

22. A method of claim 5 wherein said selective dopamine D<sub>4</sub> receptor agonist is 1000 fold more selective for the D<sub>4</sub> receptor than for the D<sub>2</sub> receptor.

30

22. A method of treating sexual dysfunction in a mammal comprising administering to a mammal in need of such treatment a therapeutically effective amount of a selective dopamine D<sub>4</sub> receptor agonist or a pharmaceutically acceptable salt thereof wherein said agonist does not cause significant emesis.

23. A method of treating male sexual dysfunction in a mammal comprising administering to a mammal in need of such treatment a therapeutically effective amount of a selective dopamine D<sub>4</sub> receptor agonist or a pharmaceutically acceptable salt thereof wherein said  
5 agonist does not cause significant emesis.

24. A method of treating female sexual dysfunction in a mammal comprising administering to a mammal in need of such treatment a therapeutically effective amount of a selective dopamine D<sub>4</sub> receptor agonist or a pharmaceutically acceptable salt thereof wherein  
10 said agonist does not cause significant emesis.

25. A method of treating male erectile dysfunction in a mammal comprising administering to a mammal in need of such treatment a therapeutically effective amount of a selective dopamine D<sub>4</sub> receptor agonist or a pharmaceutically acceptable salt thereof wherein  
15 said agonist does not cause significant emesis.

26. A method of treating sexual dysfunction in a mammal comprising administering to a mammal in need of such treatment a therapeutically effective amount of a selective dopamine D<sub>4</sub> receptor agonist or a pharmaceutically acceptable salt thereof in combination with a  
20 pharmaceutically acceptable carrier.

27. A method of treating male sexual dysfunction in a mammal comprising administering to a mammal in need of such treatment a therapeutically effective amount of a selective dopamine D<sub>4</sub> receptor agonist or a pharmaceutically acceptable salt thereof in combination  
25 with a pharmaceutically acceptable carrier.

28. A method of treating female sexual dysfunction in a mammal comprising administering to a mammal in need of such treatment a therapeutically effective amount of a selective dopamine D<sub>4</sub> receptor agonist or a pharmaceutically acceptable salt thereof in  
30 combination with a pharmaceutically acceptable carrier.

29. A method of treating male erectile dysfunction in a mammal comprising administering to a mammal in need of such treatment a therapeutically effective amount of a selective dopamine D<sub>4</sub> receptor agonist or a pharmaceutically acceptable salt thereof in combination with a pharmaceutically acceptable carrier.

5

30. A method of treating male erectile dysfunction comprising administering to a mammal in need of such treatment a therapeutically effective amount of one or more selective dopamine D<sub>4</sub> receptor agonists in combination with a phosphodiesterase 5 inhibitor or an adrenoceptor antagonist

10

0995974-10701